Suven Pharmaceuticals and Cohance Lifesciences have unveiled a proposed scheme of amalgamation aimed at merging the operations of both entities. The anticipated completion of the transaction is set within the next 12-15 months, pending the acquisition of all pertinent shareholder and regulatory approvals.
Cohance, functioning as a Contract Development and Manufacturing Organization (CDMO) and a merchant Active Pharmaceutical Ingredients (API) platform, boasts a global presence, particularly in selected low to mid-volume molecules, along with expertise in its Antibody Drug Conjugates (ADC) platform.
As reported by businessline, through this merger, Suven is poised to solidify its position as a diversified leader in CDMO and API services within the pharmaceutical industry. The amalgamation promises to foster three distinct avenues for growth: pharmaceutical CDMO, specialty chemicals CDMO, and APIs.
